Aegerion Pharmaceuticals plans to price public offering of its shares

Jefferies and J.P. Morgan are bookrunners for sale of common stock

By Devika Patel

Knoxville, Tenn., June 13 - Aegerion Pharmaceuticals, Inc. will price a public offering of common stock with a 30-day greenshoe option, according to a preliminary prospectus supplement filed Wednesday with the Securities and Exchange Commission.

Jefferies & Co., Inc. and J.P. Morgan Securities LLC are the joint bookrunning managers, and Leerink Swann LLC, Canaccord Genuity Inc. and Needham & Co., LLC are co-managers.

The company's stock (Nasdaq: AEGR) closed at $16.79 per share on June 12.

Proceeds will be used to advance the clinical development of lomitapide, as well as for working capital, capital expenditures and general corporate purposes.

Aegerion is a Cambridge, Mass., specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.